A randomized open-label phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Brief description of study

If you have been diagnosed with advanced melanoma that has previously been treated or advanced melanoma that is unable to be surgically removed, you may qualify for this Phase 2 study. The main goal of this study is to evaluate how well spartalizumab in combination with LAG525, capmatinib, or canakinumab might work in treating patients with advanced melanoma.

Clinical Study Identifier: s18-00341
ClinicalTrials.gov Identifier: NCT03484923
Principal Investigator: Jeffrey S. Weber.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.